Sanofi SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Belén Garijo López
- Full Time Employees
- 76,493
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 46, avenue de la Grande ArmEe Paris IF France 75017
- IPO Date
- Jul 1, 2002
- Website
- sanofi.com
- Similar Companies
- Business
- Sanofi is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of therapeutic solutions and vaccines. Its core product offerings encompass prescription medicines in immunology and inflammation, oncology, rare diseases, cardiovascular, central nervous system, diabetes, internal medicine, thrombosis, vaccines, and consumer healthcare. Key products include specialty care drugs such as Dupixent for immunology; Myozyme and Fabrazyme for rare diseases; a broad vaccine portfolio including bacterial and viral vaccines; and general medicines like antibiotics and over-the-counter brands. Sanofi operates through key segments including Specialty Care, Vaccines, and General Medicines, serving diverse markets worldwide. Founded in 2004 and headquartered in Paris, France, Sanofi's operations span across Europe, the Americas, Asia, and other regions. In recent developments, Sanofi has pursued a strategic transformation to become a pure biopharma company by divesting its consumer healthcare segment, now named Opella, in collaboration with Clayton, Dubilier & Rice as part of forming an independent global consumer healthcare entity. This shift reflects Sanofi's focus on innovative pharmaceuticals and vaccines. The company reorganized its business structure into three main global units: Specialty Care, Vaccines, and General Medicine. Sanofi continues to advance its pipeline aggressively with significant new product launches planned, underscored by sustained growth projections in immunology and vaccines, aiming for new vaccine sales exceeding €10 billion by 2030 and over €22 billion in immunology sales. The company is firmly investing in R&D and AI-driven innovation to drive future growth, with recent pipeline expansions including advanced immunology treatments and new vaccines programs in collaboration with partners like SK bioscience. Sanofi's portfolio consolidation also includes brand unification under the Sanofi name, merging units like Sanofi Genzyme and Sanofi Pasteur into its core brand identity. This rebranding effort secured Sanofi recognition such as the 2024 REBRAND 100 global award. The company maintains a strong focus on therapeutic categories such as immunology, oncology, rare diseases, and vaccines, augmenting its broad geographical footprint and targeting patients worldwide with both rare and common conditions. The combination of specialty care, vaccines, and general medicines segments into one Biopharma segment reflects the company’s streamlined strategy towards maximizing life sciences innovation and market impact. This description integrates Sanofi’s comprehensive product range, recent strategic business realignments, and its ongoing commitment to innovation, research, and global healthcare provision. Sanofi remains one of the leading players worldwide in pharmaceuticals and vaccines, headquartered in Paris with a global presence and a history dating back to foundational breakthroughs in vaccine development since its establishment in 2004. The company’s latest corporate moves emphasize its ambition to grow through new product launches and significant operational refinements aimed at long-term profitability and scientific advancement. This profile is based on the latest publicly available data as of late 2025 about Sanofi’s products, business segments, and strategic changes.
Company News
Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System
Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)
Press Release : Availability of the aide-mémoire for Q3 2026 results
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies